All News about Foghorn Therapeutics Inc![]() ![]() ![]() ![]()
Foghorn Therapeutics: Q4 Earnings Insights
March 07, 2024
Via Benzinga
![]()
What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
August 07, 2023
Via Benzinga
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via Benzinga
![]() ![]()
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024
Via GlobeNewswire
![]() ![]()
Foghorn Therapeutics Announces CFO Departure
January 03, 2024
Via GlobeNewswire
![]() ![]() ![]() ![]() ![]() ![]() Via GlobeNewswire
![]() ![]()
Foghorn Therapeutics Announces Chief Medical Officer Succession
August 08, 2023
Via GlobeNewswire
![]()
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
Penticton Herald
Phone number: 250-492-4002
E-mail: csr@ok.bc.ca
Address: 186 Nanaimo Ave. W.
Penticton, BC V2A 1N4
© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.